I perform an analysis of the AGILE trial that came out in NEJM today;  I find 6 huge problems.  Follow PS on twitter; and write to us to let us know what you think

4.50 - Ivosidenib & Aza vs Aza, the AGILE, 6 huge problems; Journal club

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Asco Prequel - We talk about what to look for

Should trials have carbon footprint as an endpoint?

A SM crossover - Cifu, Prasad, Mandrola

My grand rounds; Beta blockers post MI
Single center vs multicenter RCT
Masks
Boosters and more

When Evidence EXPIRES - My Grand Rounds Today at Mt Sinai

I crossover SM podcast; Harvard med students video, Justice curriculum, Masking half the year

Cifu, Mandrola, Prasad - SM crossover

Patient advocates, Pharma funding, and is MRD a suitable endpoint

4.50 - Ivosidenib & Aza vs Aza, the AGILE, 6 huge problems; Journal club

Download our free app to listen on your phone